Precision targeting of <i>CCNE1</i>-amplified tumors-lessons from BLU-222 and beyond. [PDF]
Rantanen F, Ungureanu D.
europepmc +1 more source
Efficacy and Mechanisms of CDK4/6 Inhibitors in Breast Cancer: Advancing Targeted Therapeutic Strategies. [PDF]
Patwekar M +5 more
europepmc +1 more source
p16 expression confers sensitivity to CDK2 inhibitors in cyclin E1-driven ovarian cancers. [PDF]
Sine CC +7 more
europepmc +1 more source
Emerging Strategies to Inhibit the G1/S Transition for Cancer Therapy. [PDF]
Rubin SM, Sage J, Skotheim JM.
europepmc +1 more source
Histological and Genetic Markers of Cellular Senescence in Keratinocyte Cancers and Actinic Keratosis: A Systematic Review. [PDF]
Sobolewski P +4 more
europepmc +1 more source
Immunohistochemical Expression of p16, p53, BCL2, and Cyclin D1 in Gastrointestinal Stromal Tumors: Correlation With Clinicopathological Parameters. [PDF]
Zaki MM, Enan ET, Hany H.
europepmc +1 more source
Chronic Kidney Disease and Cellular Senescence. [PDF]
Morevati M +5 more
europepmc +1 more source
Downregulation of Cyclin Kinase Inhibitors p16INK4a and p27 in Conjunctival Melanomas. [PDF]
Sarrasin E +9 more
europepmc +1 more source
Atrial myocyte senescence as a driver of atrial fibrillation: mechanisms and therapeutic implications. [PDF]
Wei Z, Li Z, Quan N.
europepmc +1 more source
[Corrigendum] CDKN2A (p16INK4A) affects the anti‑tumor effect of CDK inhibitor in somatotroph adenomas [PDF]
Chen Y +6 more
europepmc +1 more source

